Regeneron CEO Takes Industry Counterview On FTC Suit: ‘I’m Glad They’re Looking Into This’

Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit in response to the FTC’s effort to stop Amgen’s acquisition of Horizon.

New York, NY - June 22, 2022: Dr. Leonard Schleifer attends Governor Kathy Hochul announcement during groundbreaking for Regeneron facilities at company campus in Tarrytown
CEO Leonard Schleifer at a June event on Regeneron's Tarrytown, NY campus • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer weighed in on the Federal Trade Commission’s attempt to block Amgen, Inc.’s $27.8bn acquisition of Horizon Therapeutics plc, taking the stage at the Financial Times US Pharma and Biotech Summit on 16 May moments after the FTC announced it would seek to block the merger on the basis of Amgen’s rebating practices to support the federal agency’s move. 

Schleifer’s opinion of the FTC decision may be unexpected coming from a top pharma CEO, something not uncommon during the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet